Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WAYPOINT: Tezepelumab in Severe Chronic Rhinosinusitis With Nasal Polyps
jRCT2031210110Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing Tezepelumab with Placebo (2 arms). Primary endpoints: Change from baseline in total Nasal Polyp Score at Week 52 and Change from baseline in Nasal Congestion Score at Week 52. Started May 2021; status: completed.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on jRCT2031210110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210110.